Trial reportBMJ open2016
Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.
Trial report in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01962571 (Treatment of Optic Neuritis With Erythropoietin), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Therapeutic role of erythropoietin in methanol induced optic neuropathy: a systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Pooled it
- Treatment of optic neuritis with erythropoietin: impact on white matter and optic nerve MRI characteristics.Brain communications · 2026Article
- Treatment With Erythropoietin for Patients With Optic Neuritis: Long-term Follow-up.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Review
- A rare case of severe toxic optic neuropathy induced by formaldehyde vapor under working in mushroom cultivation room.International journal of ophthalmology · 2021Article
- Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone.Frontiers in immunology · 2021Review
- Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease.Investigative ophthalmology & visual science · 2020Article
- Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury.The American journal of pathology · 2020Article
- Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.Frontiers in neurology · 2020Review
- Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2019Article
- Leukemia inhibitory factor inhibits erythropoietin-induced myelin gene expression in oligodendrocytes.Molecular medicine (Cambridge, Mass.) · 2018Article
- Time to steroid treatment in severe acute optic neuritis.Brain and behavior · 2018Observational
- How to pursue EPO in MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Article
- Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials.Current neurology and neuroscience reports · 2018Review
- Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.The EPMA journal · 2018Review
- Neuroprotective effects of erythropoietin on rat retinas subjected to oligemia.Clinics (Sao Paulo, Brazil) · 2018Article
- [Optical coherence tomography in neuromyelitis optica spectrum disorders].Der Nervenarzt · 2017Review
- Association between macular degeneration and mild to moderate chronic kidney disease: A nationwide population-based study.Medicine · 2017Observational
- Vascular hypoperfusion in acute optic neuritis is a potentially new neurovascular model for demyelinating diseases.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 15 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOptic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. METHODS AND ANALYSIS: Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6 months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to ≤ 0.5 (decimal system) and an onset of symptoms within 10 days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33,000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30 months. ETHICS AND DISSEMINATION: TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. TRIAL REGISTRATION NUMBER: NCT01962571.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.